Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionAdvisor Group Holdings, Inc.
Latest Disclosed Ownership58,150 shares
Latest Disclosed Value $ 11,609,642
Advisor Group Holdings, Inc. reports 2.11% decrease in ownership of LGND / Ligand Pharmaceuticals Incorporated

On May 15, 2026 - Advisor Group Holdings, Inc. filed a 13F-HR form disclosing ownership of 58,150 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $11,609,648 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 59,405 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of -2.11% during the quarter. The current value of the position is $13,781,550 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 58,150 -1,255 -2.11 11,610 3.37 0.0099
2026-02-17 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 59,405 -41,337 -41.03 11,232 -36.95 0.0164
2025-11-14 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 100,742 94,882 1,619.15 17,813 2,691.85 0.0249
2025-09-04 2025-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 5,860 3,695 170.67 639 181.06 0.0011
2025-08-13 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 4,486 2,321 474 0.0005
2025-05-12 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 2,165 125 6.13 228 4.13 0.0005
2025-06-06 2024-12-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 2,040 -1,786 -46.68 219 -42.93 0.0005
2025-02-07 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 2,556 -1,270 261 0.0007
2024-11-13 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,826 467 13.90 383 34.98 0.0009
2024-08-13 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,359 2,722 427.32 283 515.22 0.0007
2024-05-10 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 637 -662 -50.96 47 -50.00 0.0001
2024-02-12 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,299 -244 -15.81 92 0.00 0.0002
2023-11-13 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,543 191 14.13 92 -5.15 0.0001
2023-08-21 2023-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 1,352 13 0.97 97 -1.02 0.0002
2023-08-10 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,352 13 97 0.0000
2023-05-12 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,339 -30 -2.19 98 6.52 0.0002
2023-02-10 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,369 -82 -5.65 93 -26.40 0.0002
2022-11-14 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,451 30 2.11 125 -1.57 0.0003
2022-08-10 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,421 80 5.97 127 -15.89 0.0003
2022-05-04 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,341 128 10.55 151 -18.82 0.0003
2022-02-03 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,213 -50 -3.96 186 6.29 0.0004
2021-11-05 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,263 -77 -5.75 175 0.00 0.0004
2021-08-02 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,340 -456 -25.39 175 -35.90 0.0004
2021-05-13 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,796 -565 -23.93 273 15.68 0.0007
2021-02-10 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 2,361 -1,071 -31.21 236 -28.92 0.0006
2020-11-12 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,432 -206 -5.66 332 -18.43 0.0010
2020-08-14 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,638 77 2.16 407 58.37 0.0014
2020-05-18 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 3,561 3,561 257 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.